Institution
Paul Scherrer Institute
Facility•Villigen, Switzerland•
About: Paul Scherrer Institute is a facility organization based out in Villigen, Switzerland. It is known for research contribution in the topics: Neutron & Large Hadron Collider. The organization has 9248 authors who have published 23984 publications receiving 890129 citations. The organization is also known as: PSI.
Topics: Neutron, Large Hadron Collider, Aerosol, Magnetization, Muon
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A two-directional approach for grating based x-ray differential phase contrast imaging with particular emphasis on the algorithm for proper phase retrieval to retrieve good quality and artifact-free phase images.
Abstract: We report on a two-directional approach for grating based x-ray differential phase contrast imaging. In order to retrieve good quality and artifact-free phase images for quantitative analysis and image processing, particular emphasis is put on the algorithm for proper phase retrieval. Examples of application are discussed that demonstrate the functionality of the method even in cases where the one-dimensional phase integration fails completely.
216 citations
••
TL;DR: In this paper, the high pressure phase γ-MgH2 was formed by heating the low-pressure phase MgH 2 in a multianvil press at 2 GPa pressure to 1070 K for 120 min and successive rapid quenching.
216 citations
••
TL;DR: In this article, the authors have calculated the next-to-leading-order QCD corrections to the parton processes and presented results for total cross sections and for distributions in the transverse momenta of the bottom quarks.
Abstract: Higgs-boson production in association with bottom quarks, $p\overline{p}/pp\ensuremath{\rightarrow}b\overline{b}H+X,$ is one of the most important discovery channels for supersymmetric Higgs particles at the Tevatron and the LHC. We have calculated the next-to-leading-order QCD corrections to the parton processes $q\overline{q},gg\ensuremath{\rightarrow}b\overline{b}H$ and present results for total cross sections and for distributions in the transverse momenta of the bottom quarks. The QCD corrections reduce the renormalization and factorization scale dependence and thus stabilize the theoretical predictions, especially when the Higgs-boson is produced in association with high-${p}_{T}$ bottom quarks. The next-to-leading-order predictions for the total cross-section are in reasonable numerical agreement with calculations based on bottom-quark fusion $b\overline{b}\ensuremath{\rightarrow}H$.
216 citations
••
TL;DR: The results delineate a distinct molecular mechanism of action for the inhibition of microtubule assembly by clinically relevant agents, and provide a structural basis for the rational design of potent microtubules-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.
Abstract: The recent success of antibody–drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents Here, we determined the high-resolution crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184 Consistent with biochemical and mutagenesis data, we found that the two compounds bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands Our results delineate a distinct molecular mechanism of action for the inhibition of microtubule assembly by clinically relevant agents They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer
215 citations
••
TL;DR: In this article, the authors report on the calculation of the full next-to-leading-order QCD corrections to the production of ttbb final states at the LHC, which deliver a serious background contribution to production of a Higgs boson (decaying into a bb pair) in association with a tt pair.
Abstract: We report on the calculation of the full next-to-leading-order QCD corrections to the production of ttbb final states at the LHC, which deliver a serious background contribution to the production of a Higgs boson (decaying into a bb pair) in association with a tt pair. While the corrections significantly reduce the unphysical scale dependence of the leading-order cross section, our results predict an enhancement of the ttbb production cross section by a K factor of about 1.8.
215 citations
Authors
Showing all 9348 results
Name | H-index | Papers | Citations |
---|---|---|---|
Andrea Bocci | 172 | 2402 | 176461 |
Tobin J. Marks | 159 | 1621 | 111604 |
Wolfgang Wagner | 156 | 2342 | 123391 |
David D'Enterria | 150 | 1592 | 116210 |
Andreas Pfeiffer | 149 | 1756 | 131080 |
Christoph Grab | 144 | 1359 | 144174 |
Maurizio Pierini | 143 | 1782 | 104406 |
Alexander Belyaev | 142 | 1895 | 100796 |
Ajit Kumar Mohanty | 141 | 1124 | 93062 |
Felicitas Pauss | 141 | 1623 | 104493 |
Chiara Mariotti | 141 | 1426 | 98157 |
Luc Pape | 141 | 1441 | 130253 |
Rainer Wallny | 141 | 1661 | 105387 |
Roland Horisberger | 139 | 1471 | 100458 |
Emmanuelle Perez | 138 | 1550 | 99016 |